MORGRIDGE INSTITUTE FOR RESEARCH, INC.

MADISON, WI

OncologyCAR-TPhase II

What changed

Phase I trial registered: Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults

2w agoTrial registeredJul 1, 2026Source filing (opens the source filing in a new tab)

Momentum

98no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,171 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE1 registered
Jul 1, 2026
Blood Disease · NOT_YET_RECRUITING · sponsor: University of Wisconsin, Madison · Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults
ClinicalTrials.gov · NCT04806347 (opens the source filing in a new tab)
Trial
PHASE2 registered
Sep 30, 2024
Anal Cancer · RECRUITING · sponsor: Dustin Deming · Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
ClinicalTrials.gov · NCT06493019 (opens the source filing in a new tab)
Trial
PHASE2 registered
Oct 13, 2023
Metastatic Colorectal Cancer · RECRUITING · sponsor: University of Wisconsin, Madison · Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
ClinicalTrials.gov · NCT05854498 (opens the source filing in a new tab)
Grant
R01 · $647k · non-dilutive
Aug 1, 2023
MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI SKALA, MELISSA CAROLINE · NCI · award ends Jul 31, 2028 · Label-free imaging of CAR T cell metabolism
NIH RePORTER · NIH RePORTER 11138657 (opens the source filing in a new tab)
Grant
R01 · $546k · non-dilutive
Jun 15, 2023
UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DANEMAN, RICHARD · NIA · award ends May 31, 2028 · Neurovascular circadian oscillation in health and Alzheimer's disease
NIH RePORTER · NIH RePORTER 11457082 (opens the source filing in a new tab)
Grant
U19 · $110k · non-dilutive
May 16, 2023
UNIVERSITY OF WISCONSIN-MADISON · PI SAHA, KRISHANU · NINDS · award ends Apr 30, 2026 · Administrative Core
NIH RePORTER · NIH RePORTER 11099753 (opens the source filing in a new tab)
Grant
U19 · $462k · non-dilutive
May 16, 2023
UNIVERSITY OF WISCONSIN-MADISON · PI SAHA, KRISHANU · NINDS · award ends Apr 30, 2026 · Streamlined development of an IND with the silica nanocapsule loaded with Cas9 genome editors to disrupt the dominant BEST1 mutant allele
NIH RePORTER · NIH RePORTER 11099782 (opens the source filing in a new tab)
Grant
U19 · $4.3M · non-dilutive
May 16, 2023
UNIVERSITY OF WISCONSIN-MADISON · PI SAHA, KRISHANU · NINDS · award ends Apr 30, 2026 · The CRISPR Vision Program: Nonviral Genome Editing Platforms to Treat Inherited Retinal Channelopathies
NIH RePORTER · NIH RePORTER 11099752 (opens the source filing in a new tab)
Grant
R01 · $608k · non-dilutive
Apr 15, 2023
UNIVERSITY OF WISCONSIN-MADISON · PI SHUSTA, ERIC V · NINDS · award ends Mar 31, 2028 · Identifying the role of notch3 in brain pericyte function in health and Alzheimer's disease
NIH RePORTER · NIH RePORTER 10829255 (opens the source filing in a new tab)
Grant
R01 · $216k · non-dilutive
Apr 1, 2023
MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI SKALA, MELISSA CAROLINE · NCI · award ends Mar 31, 2028 · Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids
NIH RePORTER · NIH RePORTER 11211674 (opens the source filing in a new tab)
Grant
R01 · $663k · non-dilutive
Apr 1, 2023
MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI SKALA, MELISSA CAROLINE · NCI · award ends Mar 31, 2028 · Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids
NIH RePORTER · NIH RePORTER 11285357 (opens the source filing in a new tab)
Grant
R01 · $56k · non-dilutive
Apr 1, 2023
MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI SKALA, MELISSA CAROLINE · NCI · award ends Mar 31, 2028 · Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids
NIH RePORTER · NIH RePORTER 11473218 (opens the source filing in a new tab)
Grant
R01 · $619k · non-dilutive
Apr 1, 2023
MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI SKALA, MELISSA CAROLINE · NHLBI · award ends Mar 31, 2027 · Label-free single-cell imaging for quality control of cardiomyocyte biomanufacturing
NIH RePORTER · NIH RePORTER 11309633 (opens the source filing in a new tab)
Grant
UH3 · $340k · non-dilutive
Jul 1, 2021
UNIVERSITY OF WISCONSIN-MADISON · PI KIMPLE, RANDALL J. · NIDCR · award ends May 31, 2028 · Intra-salivary gland autotransplantation of marrow mesenchymal stromal cells for treatment of radiation induced xerostomia
NIH RePORTER · NIH RePORTER 11368829 (opens the source filing in a new tab)
Trial
PHASE2 registered
Oct 19, 2020
Metastatic Colorectal Cancer · ACTIVE_NOT_RECRUITING · sponsor: University of Wisconsin, Madison · Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
ClinicalTrials.gov · NCT04587128 (opens the source filing in a new tab)
Grant
P30 · $5.2M · non-dilutive
Apr 25, 1997
UNIVERSITY OF WISCONSIN-MADISON · PI CAPITINI, CHRISTIAN · NCI · award ends Mar 31, 2028 · UW Comprehensive Cancer Center Support
NIH RePORTER · NIH RePORTER 11178501 (opens the source filing in a new tab)
Grant
P30 · $141k · non-dilutive
Apr 25, 1997
UNIVERSITY OF WISCONSIN-MADISON · PI DEMING, DUSTIN A · NCI · award ends Mar 31, 2028 · Developmental Therapeutics
NIH RePORTER · NIH RePORTER 11178524 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 83%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 1.00name similarity 100% · semantic similarity 83% · shared principal investigator / founder · same city · same therapeutic area
Shared principal investigator or founder links the grant record at 1.00name similarity 100% · shared principal investigator / founder · same city · same therapeutic area
Shared principal investigator or founder links the grant record at 1.00name similarity 100% · shared principal investigator / founder · same city · same therapeutic area
Shared principal investigator or founder links the grant record at 0.98name similarity 100% · shared principal investigator / founder · same city
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase I trial registered: Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults
2w agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
5w agoTrial registeredSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Neurovascular circadian oscillation in health and Alzheimer's disease
5w agoGrant renewalSource (opens the source filing in a new tab)
NIH UH3 · $0.3M · Intra-salivary gland autotransplantation of marrow mesenchymal stromal cells for treatment of radiation induced xerostomia
2mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Identifying the role of notch3 in brain pericyte function in health and Alzheimer's disease
2mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.1M · Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids
3mo agoGrant renewalSource (opens the source filing in a new tab)
Phase II trial registered: Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
3mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
3mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids
3mo agoGrant renewalSource (opens the source filing in a new tab)
Phase II trial registered: Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
3mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
3mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Label-free single-cell imaging for quality control of cardiomyocyte biomanufacturing
4mo agoGrant renewalSource (opens the source filing in a new tab)
NIH P30 · $5.2M · UW Comprehensive Cancer Center Support
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH P30 · $0.1M · Developmental Therapeutics
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.2M · Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids
11mo agoGrant renewalSource (opens the source filing in a new tab)
NIH U19 · $0.1M · Administrative Core
Jul 2025Grant renewalSource (opens the source filing in a new tab)
NIH U19 · $0.5M · Streamlined development of an IND with the silica nanocapsule loaded with Cas9 genome editors to disrupt the dominant BEST1 mutant allele
Jul 2025Grant renewalSource (opens the source filing in a new tab)
NIH U19 · $4.3M · The CRISPR Vision Program: Nonviral Genome Editing Platforms to Treat Inherited Retinal Channelopathies
Jul 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Label-free imaging of CAR T cell metabolism
Jul 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

PHASE1 registered

PHASE2 registered

PHASE2 registered

R01 · $647k · non-dilutive

R01 · $546k · non-dilutive

U19 · $110k · non-dilutive

U19 · $462k · non-dilutive

U19 · $4.3M · non-dilutive

R01 · $608k · non-dilutive

R01 · $216k · non-dilutive

R01 · $663k · non-dilutive

R01 · $56k · non-dilutive

R01 · $619k · non-dilutive

UH3 · $340k · non-dilutive

PHASE2 registered

P30 · $5.2M · non-dilutive

P30 · $141k · non-dilutive